Elevation of high-density lipoprotein cholesterol in humans during long- term therapy with Amiodarone

American Journal of Cardiology

Volumn 83, Issue 2, 1999, Pages 296-300

  Pollak, P Timothy ^a,b   Tan, Meng H ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

^b Queen Elizabeth II HSC ^*  (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; CHOLESTEROL; DEETHYLAMIODARONE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHOLIPID; THYROTROPIN; THYROXINE; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; HEART ARRHYTHMIA; HUMAN; LONG TERM CARE; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ADULT; AGED; AMIODARONE; ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIA; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; FEMALE; HUMANS; LIPIDS; MALE; MIDDLE AGED; RISK FACTORS; THYROTROPIN;

EID: 0033556030     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(98)00846-7     Document Type: Article

References (20)

1. Gill J, Heel RC, Fitton A. Amiodarone. An overview of its pharmacological properties, and review of its therapeutic use in cardiac arrhythmias. Drugs 1992;43:69-110.
2. Ceremuzynski L. Secondary prevention after myocardial infarction with class III antiarrhythmic drugs. Am J Cardiol 1993;72(suppl):82F-86F.
3. Greene HL. The CASCADE Study: randomized antiarrhythmic drug therapy in survivors of cardiac arrest in Seattle. CASCADE Investigators. Am J Cardiol 1993;72(suppl):70F-74F.
4. Doval HC, Nul DR, Grancelli HO, Perrone SV, Bortman GR, Curiel R. Randomised trial of low-dose amiodarone in severe congestive heart failure. Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA). Lancet 1994;344:493-498.
5. Albert SG, Alves LE, Rose EP. Thyroid dysfunction during chronic amiodarone therapy. J Am Coll Cardiol 1987;9:175-183.
6. Pritchard DA, Singh BN, Hurley PJ. Effects of amiodarone on thyroid function in patients with ischaemic heart disease. Br Heart J 1975;37:856-860.
7. Kannan R, Pollak A, Singh BN. Elevation of serum lipids after chronic administration of amiodarone in rabbits. Atherosclerosis 1982;44:19-26.
8. Pollak PT, Sharma AD, Carruthers SG. Elevation of serum total cholesterol and triglyceride levels during amiodarone therapy. Am J Cardiol 1988;62:562-565.
9. Pollak PT, Sharma AD, Carruthers SG. Correlation of amiodarone dosage, heart rate, QT interval and corneal microdeposits with serum amiodarone and desethylamiodarone concentrations. Am J Cardiol 1989;64:1138-1143.
10. Lopes-Virella MF, Stone P, Ellis S, Colwell JA. Cholesterol determination in high-density lipoproteins separated by three different methods. Clin Chem 1977; 23:882-884.
11. Dolphin PJ, Breckenridge WC, Dolphin MA, Tan MH. The lipoproteins of human umbilical cord blood: apolipoproteins and lipid levels. Atherosclerosis 1984;51:109-122.
12. Pollak PT. A systematic review and critical comparison of internal standards for the routine liquid chromatographic assay of amiodarone and desethylamiodarone. Ther Drug Monit 1996;18:168-178.
13. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA 1993;269:3015-3023.
14. LaRosa JC, Hunninghake D, Bush D, Criqui MH, Getz GS, Gotto AM Jr, Grundy SM, Rakita L, Robertson RM, Weisfeldt ML, Cleeman JI. The cholesterol facts. A summary of the evidence relating dietary fats, serum cholesterol, and coronary heart disease. A joint statement by the American Heart Association and the National Heart, Lung, and Blood Institute. The Task Force on Cholesterol Issues, American Heart Association. Circulation 1990;81:1721-1733.
15. Stampfer MJ, Sacks FM, Salvini S, Willett WC, Hennekens CH. A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction. N Engl J Med 1991;325:373-381.
16. Assmann G, Schulte H, von Eckardstein A, Huang Y. High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis 1996;124(suppl):S11-S20.
17. van Beeren HC, Bakker O, Wiersinga WM. Structure-function relationship of the inhibition of the 3,5,3'- triiodothyronine binding to the alphal- and betal-thyroid hormone receptor by amiodarone analogs. Endocrinology 1996;137: 2807-2814.
18. Hudig F, Bakker O, Wiersinga WM. Tri-iodothyronine prevents the amiodarone-induced decrease in the expression of the liver low-density lipoprotein receptor gene. J Endocrinol 1997;152:413-421.
19. Singh BN, Nademanee K. Amiodarone and thyroid function: clinical implications during antiarrhythmic therapy. Am Heart J 1983;106:857-869.
20. Chatelain P, Brasseur R. A conformational analysis study of the interaction of amiodarone and cholesterol with lysophosphatidylcholine. Biochem Pharmacol 1991;41:1639-1647.